Top

Published in:

01-02-2013 | Original Research

Expression and Function of Dectin-1 is Defective in Monocytes from Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis

Authors: Claudia Salazar-Aldrete, Marta Galán-Díez, Elena Fernández-Ruiz, Perla Niño-Moreno, Lizbeth Estrada-Capetillo, Carlos Abud-Mendoza, Esther Layseca-Espinosa, Lourdes Baranda, Roberto González-Amaro

Published in: Journal of Clinical Immunology | Issue 2/2013

Abstract

The aim of this work was to study the expression and function of the innate immune receptor dectin-1 in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). We studied twenty-six patients with SLE not receiving immunosuppressive therapy, twenty-six patients with RA, and fifteen controls. We found that monocytes from SLE patients showed a diminished expression of dectin-1 compared to healthy controls, and an inverse correlation between percent of dectin-1⁺ cells and the disease activity score was detected. In addition, cells from SLE patients showed an abnormal calcium flux response induced by dectin-1 ligands as well as an enhanced release of IL-1β, IL-6 and TNF-α, but not IL-23, upon dectin-1 engagement. Monocytes from patients with RA also showed a diminished expression, and a defective function of dectin-1. Our data suggest that dectin-1 receptor defects could contribute to the pathogenesis of autoimmune inflammatory conditions.

Reid DM, Gow NA, Brown GD. Pattern recognition: recent insights from Dectin-1. Curr Opin Immunol. 2009;21:30–7.PubMedCrossRef

Cook D, Pisetsky D, Schwartz DA. Toll-like receptors in the pathogenesis of human disease. Nat Immunol. 2004;28:975–9.CrossRef

Beutler BA. TLRs and innate immunity. Blood. 2009;113:1399–407.PubMedCrossRef

Brown GD. Dectin-1: a signaling not-TLR pattern-recognition receptor. Nat Rev Immunol. 2006;6:33–43.PubMedCrossRef

Willment JA, Marshall AS, Reid DM, Williams DL, Wong SY, Gordon S, Brown GD. The human β-glucan receptor is widely expressed and functionally equivalent to murine Dectin-1 on primary cells. Eur J Immunol. 2005;35:1539–47.PubMedCrossRef

Hollmig ST, Ariizumi K, Cruz Jr PD. Recognition of non-self polysaccharides by C-type lectin receptors dectin-1 and dectin-2. Glycobiology. 2009;19:568–75.PubMedCrossRef

Rothfuchs AG, Bafica A, Feng CG, Egen JG, Williams DL, Brown GD, Sher A. Dectin-1 interaction with Mycobacterium tuberculosis leads to enhanced IL-12p40 production by splenic dendritic cells. J Immunol. 2007;179:3463–71.PubMed

Rosas M, Liddiard K, Kimberg M, Faro-Trindade I, McDonald JU, Williams DL, Brown GD, Taylor PR. The induction of inflammation by dectin-1 in vivo is dependent on myeloid cell programming and the progression of phagocytosis. J Immunol. 2008;181:3549–57.PubMed

Li B, Cramer D, Wagner S, Hansen R, King C, Kakar S, Ding C, Yan J. Yeast glucan particles activate murine resident macrophages to secrete proinflammatory cytokines via MyD88- and Syk kinase-dependent pathways. Clin Immunol. 2007;124:170–81.PubMedCrossRef

10.

Higashi T, Hashimoto K, Takagi R, Mizuno Y, Okazaki Y, Tanaka Y, Matsushita S. Curdlan induces DC-mediated Th17 polarization via Jagged-1 activation in human dendritic cells. Allergol Int. 2010;59:161–6.PubMedCrossRef

11.

Kattah MG, Wong M, Yocum MD, Utz PJ. Cytokines secreted in response to toll-like receptor ligand stimulation modulate differentiation of human Th17 cells. Arthritis Rheum. 2008;58:1619–29.PubMedCrossRef

12.

Leibundgut-Landmann S, Gross O, Robinson MJ, Osorio F, Slack EC, Tsoni SV, Schweighoffer E, Tybulewicz V, Brown GD, Ruland J, Reis e Sousa C. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol. 2007;8:630–8.PubMedCrossRef

13.

Gringhuis SI, den Dunnen J, Litjens M, van der Vlist M, Wevers B, Bruijns SC, Geijtenbeek TB. Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-κB activation through Raf-1 and Syk. Nat Immunol. 2009;10:203–13.PubMedCrossRef

14.

Karumuthil-Melethil S, Perez N, Li R, Vasu C. Induction of innate immune response through TLR2 and dectin 1 prevents type 1 diabetes. J Immunol. 2008;181:8323–34.PubMed

15.

Weck MM, Appel S, Werth D, Sinzger C, Bringmann A, Grünebach F, Brossart P. hDectin-1 is involved in uptake and cross-presentation of cellular antigens. Blood. 2008;111:4264–72.PubMedCrossRef

16.

Nickerson KM, Christensen SR, Shupe J, Kashgarian M, Kim D, Elkon K, Shlomchik MJ. TLR9 regulates TLR7- and MyD88-dependent autoantibody production and disease in a murine model of lupus. J Immunol. 2010;184:1840–8.PubMedCrossRef

17.

Yoshitomi H, Sakaguchi N, Kobayashi K, Brown GD, Tagami T, Sakihama T, Hirota K, Tanaka S, Nomura T, Miki I, Gordon S, Akira S, Nakamura T, Sakaguchi S. A role for fungal β-glucans and their receptor Dectin-1 in the induction of autoimmune arthritis in genetically susceptible mice. J Exp Med. 2005;201:949–60.PubMedCrossRef

18.

Plantinga TS, Fransen J, Takahashi N, Stienstra R, van Riel PL, van den Berg WB, Netea MG, Joosten LA. Functional consequences of DECTIN-1 early stop codon polymorphism Y238X in rheumatoid arthritis. Arthritis Res Ther. 2010;12:R26.PubMedCrossRef

19.

Rönnblom L, Elkon KB. Cytokines as therapeutic targets in SLE. Nat Rev Rheumatol. 2010;6:339–47.PubMedCrossRef

20.

Hornung V, Latz E. Intracellular DNA recognition. Nat Rev Immunol. 2010;10:123–30.PubMedCrossRef

21.

Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of Systemic Lupus Erythematosus. Arthritis Rheum. 1982;25:1271–7.PubMedCrossRef

22.

Guzmán J, Cardiel MH, Arce-Salinas A, Sánchez-Guerrero J, Alarcón-Segovia D. Measurement of disease activity in systemic lupus erythematosus: prospective validation of 3 clinical indices. J Rheumatol. 1992;19:1551–8.PubMed

23.

Figueroa-Vega N, Galindo-Rodríguez G, Bajaña S, Portales-Pérez D, Abud-Mendoza C, Sánchez-Torres C, González-Amaro R. Phenotypic analysis of IL-10-treated, monocyte-derived dendritic cells in patients with systemic lupus erythematosus. Scand J Immunol. 2006;64:668–76.PubMedCrossRef

24.

Galán-Díez M, Arana DM, Serrano-Gómez D, Kremer L, Casasnovas JM, Ortega M, Cuesta-Domínguez A, Corbí AL, Pla J, Fernández-Ruiz E. Candida albicans beta-glucan exposure is controlled by the fungal CEK1-mediated mitogen-activated protein kinase pathway that modulates immune responses triggered through dectin-1. Infect Immun. 2010;78:1426–36.PubMedCrossRef

25.

Brown GD, Taylor PR, Reid DM, Willment JA, Williams DL, Martinez-Pomares L, Wong SY, Gordon S. Dectin-1 is a major beta-glucan receptor on macrophages. J Exp Med. 2002;196:407–12.PubMedCrossRef

26.

Ferwerda B, Ferwerda G, Plantinga TS, Willment JA, van Spriel AB, Venselaar H, Elbers CC, Johnson MD, Cambi A, Huysamen C, Jacobs L, Jansen T, Verheijen K, Masthoff L, Morré SA, Vriend G, Williams DL, Perfect JR, Joosten LA, Wijmenga C, van der Meer JW, Adema GJ, Kullberg BJ, Brown GD, Netea MG. Human Dectin-1 deficiency and mucocuntaneous fungal infections. N Engl J Med. 2009;361:1760–7.PubMedCrossRef

27.

Saijo S, Fujikado N, Furuta T, Chung SH, Kotaki H, Seki K, Sudo K, Akira S, Adachi Y, Ohno N, Kinjo T, Nakamura K, Kawakami K, Iwakura Y. Dectin-1 is required for host defense against Pneumocystis carinii but not against Candida albicans. Nat Immunol. 2007;8:39–46.PubMedCrossRef

28.

Willment JA, Lin HH, Reid DM, Taylor PR, Williams DL, Wong SY, Gordon S, Brown GD. Dectin-1 expression and function are enhanced on alternatively activated and GM-CSF-treated macrophages and are negatively regulated by IL-10, dexamethasone, and lipopolysaccharide. J Immunol. 2003;171:4569–73.PubMed

29.

Meyer-Wentrup F, Figdor CG, Ansems M, Brossart P, Wright MD, Adema GJ, van Spriel AB. Dectin-1 interaction with tetraspanin CD37 inhibits IL-6 production. J Immunol. 2007;178:154–62.PubMed

30.

Conti HR, Baker O, Freeman AF, Jang WS, Holland SM, Li RA, Edgerton M, Gaffen SL. New mechanism of oral immunity to mucosal candidiasis in hyper-IgE syndrome. Mucosal Immunol. 2011;4:448–55.PubMedCrossRef

31.

Huppler AR, Bishu S, Gaffen SL. Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy. Arthritis Res Ther. 2012;14:217.PubMedCrossRef

32.

Fernandez D, Bonilla E, Phillips P, Perl A. Signaling abnormalities in systemic lupus erythematosus as potential drug targets. Endocr Metab Immune Disord Drug Targets. 2006;6:305–11.PubMedCrossRef

33.

Alvarado-Sánchez B, Hernández-Castro B, Portales-Pérez D, Baranda L, Layseca-Espinosa E, Abud-Mendoza C, Cubillas-Tejeda AC, González-Amaro R. Regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun. 2006;27:110–8.PubMedCrossRef

34.

Shahrara S, Huang Q, Mandelin AM, Pope RM. Th17 cells in rheumatoid arthritis. Arthritis Res Ther. 2008;10:R93.PubMedCrossRef

Title: Expression and Function of Dectin-1 is Defective in Monocytes from Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Authors: Claudia Salazar-Aldrete
Marta Galán-Díez
Elena Fernández-Ruiz
Perla Niño-Moreno
Lizbeth Estrada-Capetillo
Carlos Abud-Mendoza
Esther Layseca-Espinosa
Lourdes Baranda
Roberto González-Amaro
Publication date: 01-02-2013
Publisher: Springer US
Published in: Journal of Clinical Immunology / Issue 2/2013
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-012-9821-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2013

Immune System Dysregulation Occurs During Short Duration Spaceflight On Board the Space Shuttle

Rituximab-Treated Patients Have a Poor Response to Influenza Vaccination

“Response to the Commentary on “Neuromyelitis Optica: Potential Roles for Intravenous Immunoglobulin””

Soluble levels of Osteopontin in Patients with Behcet's Disease: Association with Disease Activity and Vascular Involvement

Ethnic Differences in DNA Methyltransferases Expression in Patients with Systemic Lupus Erythematosus

Diagnostic and Prognostic Value of Low Density Lipoprotein-Containing Circulating Immune Complexes in Atherosclerosis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials